Jones 2000.

Methods	Study design: parallel RCT Study duration: not reported Study follow‐up: 96 h post‐operatively
Participants	Country: Australia Setting: single centre Inclusion criteria: women aged 50 to 70 years undergoing major gynaecological surgery (ovarian, uterine or cervical cancer) Number: treatment group (15); control group (15) Mean age ± SD (years): treatment group (60.3 ± 6.3); control group (60.3 ± 6.9) Sex (M/F): All female Exclusion criteria: kidney or hepatic impairment; bleeding diathesis; hypersensitivity to NSAIDs; asthma; medications known to interfere with tenoxicam disposition
Interventions	Treatment group Tenoxicam: 20 mg IV given 2 h before surgery Control group Normal saline: IV given 2 h before surgery
Outcomes	Pre‐operative and post‐operative (at 2, 24, 48, 72, and 96 h) measurements of CrCl, SCr, fractional excretion of sodium and potassium
Notes	Funding source: unknown quantity of support provided by Hoffmann‐La Roche & Co, Basle, Switzerland
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	Roche pharmaceuticals coded and allocated 30 patients using random number tables
Allocation concealment (selection bias)	Low risk	Study drugs made up by Roche pharmaceuticals
Blinding of participants and personnel (performance bias) All outcomes	Low risk	The allocation was not released until the end of clinical data collection
Blinding of outcome assessment (detection bias) All outcomes	Low risk	The allocation was not released until the end of clinical data collection
Incomplete outcome data (attrition bias) All outcomes	Low risk	No incomplete data
Selective reporting (reporting bias)	Low risk	Study protocol matches outcomes presented
Other bias	High risk	A commercial funding source was used for this study